Neoadjuvant hormones: 8-months regimen appears to be no better than3-month regimen

Article

Eight months of neoadjuvant hormone therapy prior to radiation therapyappears to offer no significant advantage over the standard of 3 monthsof therapy, at least in low- and intermediate-risk prostate cancer patients.

Related Videos
Keyan Salari, MD, PhD, answers a question during a Zoom video interview
Scott Morgan, MD, MSc, FRCPC, answers a question during a Zoom video interview
Illustration of prostate | Image Credit: © Judith - stock.adobe.com
Megan S. Bradley, MD, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Daniel J. Heidenberg, MD, answers a question during a Zoom video interview
African American patient explaining issues to Asian doctor using tablet | Image Credit: © rocketclips - stockadobe.com
© 2024 MJH Life Sciences

All rights reserved.